Cap Innov'Est
VC Fund
Illkirch-graffenstaden, France
Cap Innov'Est is a VC fund in Illkirch-graffenstaden focused on Biotechnology and Health Care. Cap Innov’Est is a 36M€ tri-regional fund dedicated to investments in young innovative start-ups. Cap Innov’Est was launched in July 2014 and has already invested in 13 start-ups. Cap Innov’Est is supported by Fonds National d’Amorçage, the 3 Regions Alsace, Bourgogne and Franche-Comté, SAFIDI, caisses d’épargne d’Alsace etBourgogne/Franche-Comté, BNP Paribas et CIFC
- Total investments:
- 18
- Last investment:
- Lead investor:
- 44%
- Fund size:
- $49M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cap Innov'Est invests in
Stages Cap Innov'Est invests in
Countries Cap Innov'Est invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $706k–$2.8M
- Series A
- $8.2M–$8.3M
- Venture - Series Unknown
- $2.5M–$4.5M
Investment Focus
Industry
- Biotechnology 8 (44%)
- Health Care 5 (28%)
- Medical 4 (22%)
- Pharmaceutical 4 (22%)
- Manufacturing 3 (17%)
Stage
- Seed 10 (56%)
- Series A 2 (11%)
- Venture - Series Unknown 2 (11%)
- Grant 1 (6%)
Country
- France 12 (67%)
- United States 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Grivet James
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Jean-Francois Rax
Investment Manager
|
Investment Manager | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Many of our team have worked together on different projects and in different companies over the last 30-plus years. We are experienced technology, medical, health care and biotech professionals, with long, successful histories in Silicon Valley and elsewhere. | $1.1M / Seed / Oct 10, 2023 | ||
| VistaCare is an innovative French VSE specializing in medical devices. They develop, manufacture, and distribute medical devices for the treatment of the critical phase of acute and chronic wounds. The company's technology enhances the quality of life and the care pathway for patients with wounds, as well as simplifying the daily lives ofcaregivers by drastically lowering treatment times and hospital stays. | $4.5M / Venture - Series Unknown / Jan 20, 2022 | ||
| Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO.Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that coveronly the most basic requirements.Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries. | $8.3M / Series A / Jan 25, 2021 | ||
| Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a preciseadministration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were developed by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device (in clinics). Defymed owns an exclusive technology and know-how which positions its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer management. Defymed is certified ISO13485:2016. Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey. | $1.1M / Seed / May 05, 2020 | ||
| Syndivia is a biotechnology company. Syndivia's vision is to deliver the best treatment to cancer patients by harnessing unique properties of tumour hallmarks and microenvironment. | $1.1M / Seed / Dec 10, 2019 | ||
| Urania Therapeutics company is developing a unique SBDD platform for the generation of new readthrough compounds with high potential in cancer and monogenic disorders. | $3.9M / Seed / Nov 06, 2019 | ||
| Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $8.2M / Series A / Jul 06, 2018 | ||
| Medsenic is a privately held company that manufactures drugs for the treatment of autoimmune diseases. | $2.5M / Venture - Series Unknown / Feb 06, 2018 | ||
| Opencell was created in 2015 to leverage an open source telco billing project initiated in 2007 by David Meyer, their current CEO.Their mission is to provide the first agile monetization platform capable of filling the gap between costly and complex legacy billing solutions and the overly simplistic “one size fits all” SaaS solutions that coveronly the most basic requirements.Opencell is now the open source monetization and billing platform with over 40 successful implementations in multiple industries and countries. | $1.9M / Seed / Feb 01, 2018 | ||
| Inoviem Scientific is a privately-owned contract research biotech (CRB) offering preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Our pioneering technologies allow us to work in any therapeutic field and with any therapeutic compound (small chemical molecules, fragments, proteins,peptides, antibodies, etc). Our clients are any laboratories in the private or academic sphere working to develop therapeutic compounds. Our innovatory force lies with the technologies we have developed, and our strength generally resides in our ability to analyse drug-target interaction to a high degree of precision directly on crude human tissue, thus respecting physiological conditions. Our goal is to be your partner of choice for the development of drug candidates. Our technologies have the potential to bring to light information hidden within crude human tissue obtained from patients or healthy donors. Their use will significantly improve your chances of marketing your drug. As a technollogy and innovation driven CRB, Inoviem Scientific is continuously investing human and financial resources in the development of complementary technologies to bring the best technological, creative and innovative solutions to its clients. This continuous investment will reinforce our analysis power driving Inoviem Scientific to become: From preclinical to clinical: A leading explorer of drug-target interaction! | $696.5K / Grant / Apr 19, 2017 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Cap Innov'Est invest in?
Cap Innov'Est invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 18 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Cap Innov'Est invest in?
Cap Innov'Est typically joins rounds of $706k–$2.8M at Seed, $8.2M–$8.3M at Series A and $2.5M–$4.5M at Venture - Series Unknown. These are whole funding-round sizes, not Cap Innov'Est's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Cap Innov'Est took part in.
How do I contact Cap Innov'Est?
Public channels for Cap Innov'Est include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cap Innov'Est?
The team at Cap Innov'Est includes Grivet James (Investment Manager) and Jean-Francois Rax (Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
